BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 34768175)

  • 1. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin With Concomitant Piperacillin/Tazobactam vs. Cefepime or Meropenem Associated Acute Kidney Injury in General Ward Patients: A Multicenter Propensity Score-Matched Study.
    Komerdelj IA; Buckley MS; D'Alessio PA; Ziadat DS; Kobic E; Rangan P; Agarwal SK; Tinta NC; Yerondopoulos MJ; Kane-Gill SL
    J Pharm Pract; 2024 Feb; 37(1):80-87. PubMed ID: 36075000
    [No Abstract]   [Full Text] [Related]  

  • 3. A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
    Chen AY; Deng CY; Calvachi-Prieto P; Armengol de la Hoz MÁ; Khazi-Syed A; Chen C; Scurlock C; Becker CD; Johnson AEW; Celi LA; Dagan A
    Chest; 2023 Aug; 164(2):355-368. PubMed ID: 37040818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
    Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
    Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
    Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
    Lee JD; Heintz BH; Mosher HJ; Livorsi DJ; Egge JA; Lund BC
    Clin Infect Dis; 2021 Oct; 73(7):e1579-e1586. PubMed ID: 33382398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit.
    Buckley MS; Hartsock NC; Berry AJ; Bikin DS; Richards EC; Yerondopoulos MJ; Kobic E; Wicks LM; Hammond DA
    J Crit Care; 2018 Dec; 48():32-38. PubMed ID: 30172962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study.
    O'Callaghan K; Hay K; Lavana J; McNamara JF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106010. PubMed ID: 32413387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
    Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
    Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.
    Schreier DJ; Kashani KB; Sakhuja A; Mara KC; Tootooni MS; Personett HA; Nelson S; Rule AD; Steckelberg JM; Tande AJ; Barreto EF
    Clin Infect Dis; 2019 Apr; 68(9):1456-1462. PubMed ID: 30165426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
    Rungkitwattanakul D; Ives AL; Harriott NG; Pan-Chen S; Duong L
    J Chemother; 2022 Apr; 34(2):103-109. PubMed ID: 34424136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
    Blevins AM; Lashinsky JN; McCammon C; Kollef M; Micek S; Juang P
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
    Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study.
    Triffault-Fillit C; Mabrut E; Corbin K; Braun E; Becker A; Goutelle S; Chaudier P; Fessy MH; Dupieux C; Laurent F; Gunst S; Lustig S; Chidiac C; Ferry T; Valour F
    J Antimicrob Chemother; 2020 Aug; 75(8):2299-2306. PubMed ID: 32407512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime.
    Molina KC; Barletta JF; Hall ST; Yazdani C; Huang V
    J Intensive Care Med; 2020 Dec; 35(12):1434-1438. PubMed ID: 30741072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
    Peyko V; Smalley S; Cohen H
    J Pharm Pract; 2017 Apr; 30(2):209-213. PubMed ID: 26912532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.